NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, Forecast & News

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) issued its quarterly earnings data on Thursday, November, 21st. The biotechnology company reported $0.44 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.56 by $0.12. The biotechnology company earned $51.30 million during the quarter, compared to analyst estimates of $55.95 million. Enanta Pharmaceuticals had a return on equity of 10.46% and a net margin of 22.60%. Enanta Pharmaceuticals's quarterly revenue was down 23.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.30 earnings per share. View Enanta Pharmaceuticals' Earnings History.

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for Enanta Pharmaceuticals.

4 brokerages have issued 12 month target prices for Enanta Pharmaceuticals' stock. Their forecasts range from $57.00 to $130.00. On average, they expect Enanta Pharmaceuticals' share price to reach $101.33 in the next year. This suggests a possible upside of 58.1% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.

News articles about ENTA stock have been trending somewhat positive on Sunday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Enanta Pharmaceuticals earned a coverage optimism score of 1.3 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View News Stories for Enanta Pharmaceuticals.

Some companies that are related to Enanta Pharmaceuticals include Ascendis Pharma A/S (ASND), Global Blood Therapeutics (GBT), Mirati Therapeutics (MRTX), FibroGen (FGEN), BridgeBio Pharma (BBIO), United Therapeutics (UTHR), Intercept Pharmaceuticals (ICPT), Blueprint Medicines (BPMC), Taro Pharmaceutical Industries (TARO), Nektar Therapeutics (NKTR), Evotec (EVTCY), Alkermes (ALKS), HUTCHISON CHINA/S (HCM), GW Pharmaceuticals PLC- (GWPH) and SAGE Therapeutics (SAGE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Pandora Media (P), Ryder System (R), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), Ford Motor (F), Alibaba Group (BABA), Wells Fargo & Co (WFC) and Tesla (TSLA).

Enanta Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (4.49%), Krensavage Asset Management LLC (2.53%), Man Group plc (1.50%), Granahan Investment Management Inc. MA (0.76%), Russell Investments Group Ltd. (0.49%) and Rhumbline Advisers (0.26%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, First Trust Advisors LP, Dupont Capital Management Corp, Alps Advisors Inc., Navellier & Associates Inc, Systematic Financial Management LP, New York State Teachers Retirement System and Barclays PLC. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, George Golumbeski, Nathaniel S Gardiner and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals.

ENTA stock was acquired by a variety of institutional investors in the last quarter, including Man Group plc, Squarepoint Ops LLC, State Street Corp, Krensavage Asset Management LLC, SG Americas Securities LLC, Voloridge Investment Management LLC, California Public Employees Retirement System and Russell Investments Group Ltd.. View Insider Buying and Selling for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $64.08.

Enanta Pharmaceuticals has a market capitalization of $1.26 billion and generates $205.20 million in revenue each year. The biotechnology company earns $46.38 million in net income (profit) each year or $2.21 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.View Additional Information About Enanta Pharmaceuticals.

The official website for Enanta Pharmaceuticals is http://www.enanta.com/.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]